MTA2

Across TCGA pan-cancer cohorts, MTA2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MTA2 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MTA2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MTA2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where MTA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.801	0.911	.004	42	view →
LUAD	OS	Tertile	III,IV	1.000	0.643	.006	37	view →
PDAC	OS	Median	All	0.381	0.566	.017	10	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MTA2–HNSC (OS)

Open the HNSC breakdown →